Open Access Mini Review

M2000, an Antagonist for Human TLR2 and TLR4

Mona Aslani1 and Abbas Mirshafiey*1,2

1Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

2Research Centre for Immunodeficiencies, Tehran University of Medical Sciences, Tehran, Iran

Corresponding Author

Received Date: December 16, 2018;  Published Date: May 23, 2019

Abstract

Toll-like receptors (TLRs) especially TLR2 and TLR4 play a crucial role in immunopathogenesis of autoimmune and inflammatory diseases such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS); therefore, selective blockade of these receptors or associated adaptor molecules in their signaling pathways has been developed, as a new therapeutic approach for many inflammatory diseases. The β-D-Mannuronic acid (M2000) is a new anti-inflammatory drug with immunosuppressive properties. Several in vitro and in vivo investigations have shown that this new drug is able to target the TLR2 and TLR4 signaling pathways and act as an antagonist for these receptors.

Keywords: M2000; Mannuronic acid; TLR2; TLR4; NSAIDs

Citation
Signup for Newsletter
Scroll to Top